Sanjiv Agarwala.

(.. ASCO Scientific Program 2010: Provectus Pharmaceuticals’ Phase 2 data on PV-10 accepted for presentation Provectus Pharmaceuticals, Inc. Sanjiv Agarwala, Chief, Medical Hematology and Oncology at St. Dr. As I recently noted, PV-10 is intriguing if you ask me as an oncologist since it appears to recruit immune cells to the ablation site, leading to the potential of a systemic advantage. Metastatic melanoma is a deadly and dreadful disease, and we believe PV-10 holds promise as a viable, effective and safe treatment, with minimal unwanted effects, not only for this disease, but for a broad spectral range of other cancers as well potentially.Related StoriesNew Cleveland Clinic study shows bariatric medical procedures is safe option for managing type 2 diabetes in over weight or mildly obese patientsMayo Clinic investigators discover novel mechanism linked to diabetes riskHeart attack sufferers diagnosed and treated for diabetes knowledge improved cardiac outcomes ‘Getting this prestigious award is definitely a tribute to the doctors and personnel of The Mid-Atlantic Permanente Medical Group,’ stated Dr. Loftus. When doctors across specialties together work, using advanced it to achieve excellent quality outcomes and personalized service for patients, the total results are exceptional. The Acclaim Awards, granted through AMGA's philanthropic arm, the American Medical Group Basis, honors agencies that are meeting the Institute of Medication Aims for Improvement and are taking the steps needed to become a high-performing health system while defined by AMGA.